BioSpace News Archive

Monoclonal antibodies are produced through cell division from a single ancestral or parent cell.

Medical purity analyzers refer to those instruments that are able to measure and determine quantitative and qualitative composition of mixtures of medical gases or pure medical gases.

Cubital tunnel syndrome is a peripheral medical condition of numbness, weakness, or tingling due to compression of the ulnar nerve.

Fact.MR – A Market research and competitive intelligence provider: The global endoscopy procedures estimates market was valued at US$ 223 Mn in 2021 and is expected to gain an important position in the market with a steady market size at a CAGR rate of 1.5% during the forecast period, 2022- 2032.

The leading research-driven biopharmaceutical company Boehringer Ingelheim and precision medicine software company Lifebit Biotech, Ltd. announce partnership in which Lifebit will support Boehringer Ingelheim in building a scalable data, analytics, and infrastructure platform within its IT environment.

Ascletis Pharma Inc. announces that it has submitted marketing authorization applications for ritonavir in eight additional European countries through its agent in Europe.

BioEcho Life Sciences GmbH announced a minority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors.

TakeAir, a Belgian biotechnology firm specialising in indoor air quality improvement, has announced ground-breaking new Biospheric Air Treatment technology that kills airborne viruses in buildings.

Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, to assist in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency who may be eligible to participate in a Phase 3 clinical trial.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in March 2022.